Epigral Ltd
Epigral Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Epigral Limited expects a volume growth CAGR of 10% to 15% over the next 5 years driven by capacity expansions. Epigral targets consistent volume growth of 10-15% CAGR over the next five years, driven by CAPEX expansions in CPVC resin, Epichlorohydrin, and chlorotoluene plants.
From Epigral Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Epigral Limited expects a volume growth CAGR of 10% to 15% over the next 5 years driven by capacity expansions.
- Revenue growth is anticipated at 15% to 20% CAGR over the next 4-5 years, supported by new CAPEX and increased volumes.
- Key growth drivers include ramp-up of CPVC resin and compound capacity, Epichlorohydrin (ECH) expansion, and the newly commissioned chlorotoluene plant.
- The company aims to increase revenue contribution from the Derivatives & Specialty business from 54% in FY25 to around 70%.
- The chlor-alkali integration with captive chlorine consumption is expected to improve, with target utilization at 80-90% by FY27.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned CAPEX of around Rs. 450 crore for FY 2026 focused on expanding capacities in CPVC resin (addition of 75,000 tonnes to reach 1,50,000 tonnes) and Epichlorohydrin (expanding from 50,000 to 1,00,000 tonnes by H1 FY 2027).
- Newly commissioned plants (CPVC, CPVC compound, chlorotoluene) expected to reach optimum utilization by end of FY 2026.
- Minor debottlenecking CAPEX expected for chlor-alkali (caustic soda and chlorine integration) once operating at ~90% levels; no major chlor-alkali expansion planned currently.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Epigral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹736 Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Atul Ltd (Q4 FY25)
Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…
- Vidhi Specialty Food Ingredients Ltd (Q4 FY25)
109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Chemcon Speciality Chemicals Ltd (Q4 FY25)
54.9 Crs, down 8% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Valiant Organics Ltd (Q4 FY25)
Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…
Frequently Asked Questions
What were Epigral Ltd Q4 FY25 results?
Epigral Limited expects a volume growth CAGR of 10% to 15% over the next 5 years driven by capacity expansions. Epigral targets consistent volume growth of 10-15% CAGR over the next five years, driven by CAPEX expansions in CPVC resin, Epichlorohydrin, and chlorotoluene plants.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Planned CAPEX of around Rs.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.